Healthcare - Press Releases

CRSA Joins Ryght Research Network to Accelerate Access to Novel Cancer Therapies

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The globaltransmission electron microscope marketsize is estimated to grow by USD 528.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over11.76% during the forecast period. Increasing focus on nanotechnologyis driving market growth,with a trend towardsdevelopment of new forms of transmission electron microscopes. However,high cost and heavy excise duty of transmission electron microscopes poses a challenge. Key market players include Advantest Corp., Agilent Technologies Inc., AMETEK Inc., Angstrom Advanced Inc., Bruker Corp., Carl Zeiss Stiftung, Danaher Corp., DELONG INSTRUMENTS AS, Hirox Co. Ltd., Hitachi Ltd., IXRF Inc., JEOL Ltd, NanoScience Instruments Inc., Nikon Corp., Nion, Olympus Corp., Oxford Instruments plc, Roper Technologies Inc., Thermo Fisher Scientific Inc., and VIDEOTON HOLDING ZRt.

HOUSTON, Jan. 27, 2025 /PRNewswire/ -- Sisters Network Inc. (SNI), the only nationalAfrican American breast cancer survivorship organization with 25+ survivor run affiliate chapters is proud to announce the relaunch of the Teens4Pink program, now featuring an innovative mobile app available nationwide throughApple and Google Play. Originally launched in2013,Teens4Pink is designed to educate and empower teens aged 12 to 17 to change the way women in their family think and act about breast health.

Hansen will succeed Robert Indresano as he transitions to the role of Chairman of the Board

LAKE MARY, Fla., Jan. 27, 2025 /PRNewswire/ -- The IIA releases the following statement regarding the termination of federal Inspectors General:

The national advanced primary care marketplace for employers provides access in all 50 states, with 3,000 clinics located within driving distance of >80% of the U.S. population

BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ --Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per share to stockholders during the first quarter of 2024.

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator

BRANFORD, Conn., Jan. 27, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, NJ.

BURLINGTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens.

BREA, Calif., Jan. 27, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its fourth quarter 2024 onWednesday, February 5, 2025. Envista is moving the time of the conference call and will now discuss these results beginning at 2:30 PM PTon the same date. The call will last approximately one hour.

LOS ANGELES, Jan. 27, 2025 /PRNewswire/ --Partillion Bioscience Corporation ("Partillion"), a life science tools company, announced the opening of pre-orders for its Nanovial Multicell Assay Antibody Discovery Kits. The Multicell Assay platform, which enables the co-loading of cell pairs to study cell-to-cell interactions, has been named a finalist for the Society for Laboratory Automation and Screening (SLAS) 2025 New Product Award.

Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination and Support for Caregivers

Company to Participate in Upcoming Conferences

A case study on how a mid-sized pharmaceutical company collaborated with DelveInsight to expand its asset portfolio in the Atrial Fibrillation space. DelveInsight conducted comprehensive asset prioritization, identifying the most promising Phase II therapeutic candidates for licensing opportunities. This evidence-based approach helped the client strategically align the clinical trial pipeline with growth objectives, ensuring a competitive edge in the market.

AUSTIN, Texas, Jan. 27, 2025 /PRNewswire/ --In response to a devastating start to the new year with wildfires continuing to advance through the greater Los Angeles area, Pet King Brands, leader of the veterinarian-recommended ZYMOX and Oratene pet health products, provides monetary and product donations to organizations providing relief to animals in need.

Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination and Support for Caregivers

El modelo Guiding an Improved Dementia Experience (GUIDE) tiene como objetivo aumentar la coordinacin de la atencin y el apoyo a los cuidadores

SANTA MONICA, Calif., Jan. 27, 2025 /PRNewswire/ -- In his new book - Longevity Guidebook: How to Slow, Stop, and Reverse Aging, and NOT DIE from Something Stupid - New York Times bestselling author, futurist and entrepreneur, Peter H. Diamandis, MD, describes the longevity revolution racing our way at the convergence of AI, genomics, and cellular medicine.

Event will showcase results of Company's pivotal PRIME study and include the principal investigator

LONG BEACH, Calif., Jan. 27, 2025 /PRNewswire/ -- Anivive Lifesciences, a software-driven pet health company, is pleased to announce it has secured $20MM in funding from Leonid Capital Partners ("Leonid"). Leonid is a leading investment firm focused on high-growth technology companies working in the national security industry.

SUZHOU, China, Jan. 26, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced a strategic commercialization partnership with SteinCares, a leading pharmaceutical company with over 40 years of experience anda strong presence in Latin America. Under this agreement, SteinCares will gain the commercialization rights for sugemalimab in 10 LATAM countries, including Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala and Ecuador.

SAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Robbins LLPinforms investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024. ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. The Company's lead product candidate was masofaniten, which was in clinical trial in combination with enzalutamide compared with enzalutamide alone in patients with metastatic CRPC.

Trend Predictions Unveiled: From Beauty Voyagers to Nano Neighborhoods

STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly,SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of units that was announced on November 12, 2024. Following the completed recalculation, SciBase can confirm that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share, remains unchanged. Thus, one (1) warrant of series TO 2 entitles the holder to subscribe for one (1) share at a subscription price of SEK 0.42, in accordance with the previously communicated terms and conditions for the warrants.